☆ 4.5 Review

New molecular and immunologic targets of therapy for esophageal cancer and the prospects for ongoing and future clinical trials

JOURNAL OF SURGICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

The Perioperative and Operative Management of Esophageal and Gastric Cancer

Amn Siddiqi et al.

Summary: Optimal perioperative and operative management of esophageal and gastric cancer requires a multidisciplinary approach, such as endoscopic and robotic resections, as well as CRS and HIPEC. Improvements in perioperative chemotherapy and radiation therapy not only benefit survival rates, but also make unresectable tumors operable.

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2023)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Review Oncology

Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score

A. G. Leone et al.

Summary: Immunotherapy-based regimens show clear survival benefits compared to chemotherapy alone in patients with advanced esophageal squamous cell carcinoma. The efficacy is not dependent on geographical region or treatment line. The programmed death-ligand 1 CPS status is associated with the treatment's effectiveness.

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

Yelena Y. Janjigian et al.

Summary: This study investigates the efficacy and safety of the immune checkpoint inhibitor durvalumab combined with FLOT chemotherapy in patients with resectable gastric/gastroesophageal junction cancer, and finds that the combination therapy improves clinical outcomes.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience

Steven B. Maron et al.

Summary: Subset analyses from phase III evaluation showed improved outcomes in patients with EGFR-amplified gastroesophageal adenocarcinoma. A total of 60 patients from 15 tertiary cancer centers participated in the study, with an objective response rate of 43% and a median progression-free survival of 4.6 months with EGFRi. Despite the significant benefit, only 5% of patients with EGFR-amplified GEA received EGFRi according to the clinicogenomic database analysis.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara et al.

Summary: In patients with gastro-oesophageal adenocarcinoma, nivolumab plus chemotherapy has shown superior overall survival compared to chemotherapy alone.

NATURE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020

Eileen Morgan et al.

Summary: This study provides an overview of the burden of esophageal cancer in 185 countries in the year 2020 and projections for 2040. The global incidence and mortality rates of esophageal cancer vary across countries and regions, with higher rates observed in males compared to females. The predicted burden in 2040 shows an increase in new cases and deaths from esophageal cancer.

GASTROENTEROLOGY (2022)

添加到收藏夹

Article Respiratory System

Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer

Jessica Yang et al.

THORACIC SURGERY CLINICS (2022)

添加到收藏夹

Meeting Abstract Oncology

Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.

Funda Meric-Bernstam et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian et al.

Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

NATURE (2021)

添加到收藏夹

Article Oncology

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Ben M. Eyck et al.

Summary: The preoperative chemoradiotherapy regimen according to CROSS study has shown to have a long-term overall survival benefit for patients with locally advanced resectable esophageal or junctional cancer, with a stable effect observed up to 10 years of follow-up.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly et al.

Summary: In patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab significantly improved disease-free survival compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

添加到收藏夹

Article Surgery

Surgical Management of Early Esophageal Cancer

Facundo Iriarte et al.

SURGICAL CLINICS OF NORTH AMERICA (2021)

添加到收藏夹

Article Oncology

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

Elizabeth Smyth et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

Salah-Eddin Al-Batran et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

Yung-Jue Bang et al.

FUTURE ONCOLOGY (2019)

添加到收藏夹

Editorial Material Medicine, General & Internal

HER2 and Breast Cancer - A Phenomenal Success Story

Daniel F. Hayes

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Claudia Allemani et al.

LANCET (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Integrated genomic characterization of oesophageal carcinoma

Jihun Kim et al.

NATURE (2017)

添加到收藏夹

Review Medicine, General & Internal

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

Vassiliki A. Boussiotis

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Oncology

Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics

Stanleyson V. Hato et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Hansjochen Wilke et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

P. van Hagen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung-Jue Bang et al.

LANCET (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.